8MW 2311
Alternative Names: 8MW-2311Latest Information Update: 05 Sep 2022
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antineoplastics; Interleukins; Polyethylene glycols
- Mechanism of Action Interleukin 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Aug 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV, Infusion) (NCT05416749)
- 13 Jun 2022 Mabwell (Shanghai) Bioscience plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease) (IV,Infusion) in June 2022 (NCT05416749)
- 15 Feb 2022 Preclinical trials in Solid tumours in China (Parenteral) (Mabwell (Shanghai) Bioscience pipeline, April 2022)